Patients and patents for Sirtex in Europe
Tuesday, 10 December, 2002
Sirtex Medical has treated its first European patient, suffering from advanced secondary liver cancer, with its SIR-Spheres cancer treatment at the Leicester General Hospital, the principal teaching hospital at the University of Leicester in the UK.
The procedure marks the beginning of the roll-out of the technology in Europe. Regulatory approval to market the product was received from the European Union in October.
According to CFO Peter Manley, a similar approach to the one used in the US will be taken, targeting key research and teaching hospitals in the initial phase.
But due to differences in the medical systems in European countries, Manley said that the roll-out of the treatment would not be as fast in Europe as in the US.
The initial phase will be concentrating on only four countries, the UK, France, Germany and Belgium.
As in the US, medical director Dr Bruce Gray will be directly involved in the training for the procedure. Manley said that the company was also planning to hire a medical director to be based in the US.
In addition, the company hopes that some of the hospitals already trained might be able to start training other centres.
In a separate announcement, Sirtex also noted that a patent covering its use of microspheres to deliver chemotherapeutic drugs was granted in Europe.
Manley said that the patent had been with the European patent authorities for a number of years, and was already approved in Australia and the US.
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
